An observational study in Oral Lichen Planus, Oral Cancer and Leukoplakia, sponsored by Beni-Suef University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-02-13.
Sponsored by Beni-Suef University · Observational
investigating the level of malondialdehyde (MDA) \& nitric oxide (NO) in saliva in oral premalignant and malignant lesions in order to determine their diagnostic value for the malignant and potentially malignant lesions.
Being a detrimental disease, cancer development is a very complicated process that requires many sequential steps and depends on a various number of genetic alterations and factors(1). Among these factors are the free radicals which are derived either from endogenous or exogenous sources (5). Free radicals result in an oxidative stress of the affected cells generating a body imbalance between oxidants and antioxidants (6).
In this regard, saliva has been currently used to assess this possible oxidative imbalance through various salivary biomarkers including nitric oxide (NO) and malondialdehyde (MDA). Saliva could be used as a very interesting rich medium, known for its role in diagnosis, prognosis and treatment that has become more prominent in oral diseases (6).
Nitric oxide (NO) is an intercellular messenger molecule having many important biological functions. The levels of nitric oxide in salivary secretions could be used to monitor the severity of many underlying disease processes. Moreover, malondialdehyde (MDA) has been the most frequently used biomarker of oxidative stress in many pathological conditions such as cancer. It resulted from reactive oxygen species lipid degradation and induced toxic stress in affected cells, making both biomarkers a point of focus in monitoring clinical progress of suspected lesions
142 studies on the registry are indexed under Lichen Planus, Oral; 27 are open to participants now.
This study's enrollment of 100 is above the median of 75 across 38 observational studies indexed under Lichen Planus, Oral.
Browse Lichen Planus, Oral studies →Beni-Suef University is the lead sponsor of 349 studies on the registry; 125 are open to participants now.
Counted across the registry records on this site, refreshed daily.
out patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
healthy individuals with one of the following oral lesions :
Exclusion Criteria:
MDA and NO in saliva
Diagnostic Test: salivary biomarker
MDA and NO in saliva
Diagnostic Test: salivary biomarker
MDA and NO in saliva
Diagnostic Test: salivary biomarker
MDA and NO in saliva
Diagnostic Test: salivary biomarker
MDA and NO in saliva
Diagnostic Test: salivary biomarker
MDA and NO as salivary biomarkers
Salivary MDA level in different oral lesions
The MDA level in saliva measured using ELISA kit provided by My BioSource, USA.
Time frame: 9 months
Salivary NO level in different oral lesions
The nitric oxide level in saliva measured using ELISA kit provided by My BioSource, USA.
Time frame: 9 MONTHS
Plan to share: Yes — all the data will shared once the work is published
Supporting information: Study protocol, Clinical study report
Time frame: once published
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.